Weight-Loss Jabs Investigated for Mental Health Risk

Danielle Lowe
By Danielle Lowe

Danielle Lowe is the Marketing Manager for ConsultingRoom.com, (www.consultingroom.com) the UK’s largest aesthetic information website. 


Europe's drugs regulator is conducting a review of some weight-loss jabs after being alerted to a possible link to thoughts of suicide and self-harm among users. The safety assessment will look at Wegovy, Saxenda and similar drugs, such as Ozempic, that help curb appetite.
 
Product leaflets already list suicidal thoughts as a possible side effect.
 
Suicidal behaviour is not currently listed for these prescription drugs.
 
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC), which is conducting the review, will consider whether other treatments in the same broader category of medicines, glucagon-like peptide-1 (GLP-1) receptor agonists, also need assessing. But initially, it will assess only the risks of using weight-loss medication that contains either semaglutide or liraglutide.
 
An EMA official said:
 
"The review is being carried out in the context of a signal procedure raised by the Icelandic Medicines Agency, following three case reports. A signal is an information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation.
The case reports included two cases of suicidal thoughts - one following the use of Saxenda and one after Ozempic. One additional case reported thoughts of self-injury with Saxenda. The EMA will communicate further when more information becomes available."
 
Manufacturer Novo Nordisk says patient safety is a top priority. A representative said:
 
"GLP-1 receptor agonists have been used to treat type-2 diabetes for more than 15 years and for treatment of obesity for eight years, including Novo Nordisk products such as semaglutide and liraglutide that have been in the UK market since 2018 and 2009 respectively. The safety data collected from large clinical-trial programmes and post-marketing surveillance have not demonstrated a causal association between semaglutide or liraglutide and suicidal and self-harming thoughts. Novo Nordisk is continuously performing surveillance of the data from ongoing clinical trials and real-world use of its products and collaborates closely with the authorities to ensure patient safety and adequate information to healthcare professionals."
 
The UK's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), said it was monitoring the situation.
 
Dr Alison Cave, MHRA Chief Safety Officer, said:
 
"As part of our close monitoring, any emerging evidence is routinely considered alongside other sources of information, including suspected adverse drug reactions. We will communicate any new advice to healthcare professionals and patients if appropriate. If you are experiencing suicidal thoughts or thoughts of self-harm, please seek immediate medical assistance. We ask everyone to report any suspected side effects using our Yellow Card scheme website."
CREC

Keep In Touch

Ensure you and your staff stay up-to-date with key topics shaping the field of aesthetics.

Your free digital round-up of relevant aesthetic news articles and trending items delivered directly to your inbox.

Immerse yourself in our quarterly, complimentary, themed digital magazine, compiled by award-winning editor Vicky Eldridge.

Stay informed of new technologies and receive exclusive news and offers from carefully selected aesthetic partners.